Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma

Patent metadata

Field	Value
Publication number	US-11535679-B2
Application number	US-202117558404-A
Country	US
Kind code	B2
Filing date	Dec 21, 2021
Priority date	Sep 10, 2020
Publication date	Dec 27, 2022
Grant date	Dec 27, 2022

Abstract

Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and bendamustine.

First claim

The invention claimed is:

1. A method of treating follicular lymphoma in a human subject, the method comprising administering to the subject a bispecific antibody and an effective amount of rituximab and bendamustine, wherein the bispecific antibody comprises:
(i) a first binding arm comprising a first antigen-binding region which binds to human CD3c (epsilon) and comprises a variable heavy chain (VH) region and a variable light chain (VL) region, wherein the VH region comprises the CDR1, CDR2 and CDR3 sequences that are in the VH region sequence of SEQ ID NO: 6, and the VL region comprises the CDR1, CDR2 and CDR3 sequences that are in the VL region sequence of SEQ ID NO: 7; and
(ii) a second binding arm comprising a second antigen-binding region which binds to human CD20 and comprises a VH region and a VL region, wherein the VH region comprises the CDR1, CDR2 and CDR3 sequences that are in the VH region sequence of SEQ ID NO: 13, and the VL region comprises the CDR1, CDR2 and CDR3 sequences that are in the VL region sequence of SEQ ID NO: 14;
wherein the bispecific antibody is administered at a dose of 24 mg or 48 mg, and wherein rituximab, bendamustine, and the bispecific antibody are administered in 28-day cycles,
wherein the bispecific antibody, rituximab, and bendamustine are administered in the same cycle for the first 6 cycles, and the bispecific antibody is administered alone for subsequent cycles, and wherein a priming dose of the bispecific antibody is administered on day 1 of cycle 1 and an intermediate dose is administered on day 8 of cycle 1 before the dose of 24 mg or 48 mg on days 15 and 22 of cycle 1.

2. The method of claim 1 , wherein the bispecific antibody is administered at a dose of 24 mg.

3. The method of claim 1 , wherein the bispecific antibody is administered at a dose of 48 mg.

4. The method of claim 1 , wherein the bispecific antibody is administered once every week (weekly administration) for 2.5 28-day cycles.

5. The method of claim 4 , wherein after the weekly administration, the bispecific antibody is administered once every two weeks (biweekly administration) for six 28-day cycles.

6. The method of claim 5 , wherein after the biweekly administration, the bispecific antibody is administered once every four weeks for up to two years total duration of treatment with the bispecific antibody from initiation of rituximab and bendamustine.

7. The method of claim 1 , wherein the priming dose is 0.16 mg and the intermediate dose is 0.8 mg.

8. The method of claim 1 , wherein rituximab is administered once every four weeks for six 28-day cycles.

9. The method of claim 1 , wherein bendamustine is administered once a day from day 1 to day 2 for six 28-day cycles.

10. The method of claim 1 , wherein rituximab, bendamustine, and the bispecific antibody are administered on the same day.

11. The method of claim 1 , wherein administration is performed in 28-day cycles, and wherein:
(a) the bispecific antibody is administered as follows:
(i) in cycle 1, a priming dose of 0.16 mg is administered on day 1, an intermediate dose of 0.8 mg is administered on day 8, and a dose of 24 mg is administered on days 15 and 22;
(ii) in cycles 2 and 3, a dose of 24 mg is administered on days 1, 8, 15, and 22;
(iii) in cycles 4-9, a dose of 24 mg is administered on days 1 and 15; and
(iv) in cycle 10 and subsequent cycles, a dose of 24 mg is administered on day 1;

(b) rituximab is administered on day 1 in cycles 1-6; and
(c) bendamustine is administered on days 1 and 2 in cycles 1-6.

12. The method of claim 1 , wherein administration is performed in 28-day cycles, and wherein:
(a) the bispecific antibody is administered as follows:
(i) in cycle 1, a priming dose of 0.16 mg is administered on day 1, an intermediate dose of 0.8 mg is administered on day 8, and a dose of 48 mg is administered on days 15 and 22;
(ii) in cycles 2 and 3, a dose of 48 mg is administered on days 1, 8, 15, and 22;
(iii) in cycles 4-9, a dose of 48 mg is administered on days 1 and 15; and
(iv) in cycle 10 and subsequent cycles, a dose of 48 mg is administered on day 1;

(b) rituximab is administered on day 1 in cycles 1-6; and
(c) bendamustine is administered on days 1 and 2 in cycles 1-6.

13. The method of claim 1 , wherein rituximab is administered at a dose of 375 mg/m 2 .

14. The method of claim 1 , wherein bendamustine is administered at a dose of 90 mg/m 2 .

15. The method of claim 1 , wherein the bispecific antibody is administered subcutaneously.

16. The method of claim 1 , wherein rituximab and bendamustine are administered intravenously.

17. The method of claim 1 , wherein
(a) the follicular lymphoma is previously untreated follicular lymphoma;
(b) the subject has grade 1, 2, or 3a untreated follicular lymphoma; and/or
(c) the subject has Stage II, III, or IV untreated follicular lymphoma.

18. The method of claim 1 , wherein:
(i) the first antigen-binding region of the bispecific antibody comprises a VH region comprising the amino acid sequence of SEQ ID NO: 6, and the VL region comprising the amino acid sequence of SEQ ID NO: 7; and
(ii) the second antigen-binding region of the bispecific antibody comprises a VH region comprising the amino acid sequence of SEQ ID NO: 13, and the VL region comprising the amino acid sequence of SEQ ID NO: 14.

19. The method of claim 1 , wherein the first binding arm of the bispecific antibody is derived from a humanized antibody and comprises a λ, light chain constant region comprising the amino acid sequence set forth in SEQ ID NO: 22 and/or wherein the second binding arm of the bispecific antibody is derived from a human antibody and comprises a κ light chain constant region comprising the amino acid sequence set forth in SEQ ID NO: 23.

20. The method of claim 1 , wherein the bispecific antibody is a full-length antibody with a human IgG1 constant region.

21. The method of claim 1 , wherein the bispecific antibody comprises an inert Fc region.

22. The method of claim 1 , wherein the bispecific antibody comprises a first heavy chain and a second heavy chain, wherein
(i) in both the first and second heavy chains, the amino acids in the positions corresponding to positions L234, L235, and D265 in the human IgG1 heavy chain constant region of SEQ ID NO: 15 are F, E, and A, respectively, and
(ii) in the first heavy chain, the amino acid in the position corresponding to F405 in the human IgG1 heavy chain constant region of SEQ ID NO: 15 is L, and wherein in the second heavy chain, the amino acid in the position corresponding to K409 in the human IgG1 heavy chain constant region of SEQ ID NO: 15 is R, or vice versa.

23. The method of claim 1 , wherein the bispecific antibody comprises heavy chain constant regions comprising the amino acid sequences of SEQ ID NOs: 19 and 20.

24. The method of claim 1 , wherein the bispecific antibody comprises a first heavy chain and a first light chain comprising the amino acid sequences set forth in SEQ ID NOs: 24 and 25, respectively, and a second heavy chain and a second light chain comprising the amino acid sequences set forth in SEQ ID NOs: 26 and 27, respectively.

25. The method of claim 1 , wherein the bispecific antibody is epcoritamab, or a biosimilar thereof, wherein the biosimilar comprises:
(i) a first binding arm comprising a VH region comprising the CDR1, CDR2 and CDR3 sequences that are in the VH region sequence of SEQ ID NO: 6

Assignees

• Genmab As

Inventors

• Elliott Brian
• Ahmadi Tahamtan
• Chiu Christopher W L
• Breij Esther C W

Classifications

• C07K2317/31

  multispecific · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• C07K16/2809

  against the T-cell receptor (TcR)-CD3 complex · CPC title

• A61K2039/545

  characterised by the dose, timing or administration schedule · CPC title

• C07K16/2887 Primary

  against CD20 · CPC title